Addressing the Issue at its Core
Obesity drives diabetes. Diabetes worsens obesity.
Obesity and diabetes are among today’s most urgent global health challenges. Linked by shared mechanisms of insulin resistance, chronic inflammation, and metabolic dysfunction, they don’t just co-exist, they reinforce each other.
Together, they form a vicious cycle that accelerates age-related decline, increases mortality, and drives up healthcare costs. This cycle also triggers a cascade of other chronic conditions.
At Hummsa, we’re working to break this cycle.
Our next-generation GLP - 1 therapies target the root causes to restore balance and make healthy aging accessible to all.
For millions living with diabetes, obesity, fatty liver disease, osteoporosis, and Alzheimer’s, today’s treatments come with limits.
They arrive late, after irreversible damage has begun. They manage symptoms, not the root cause. They rely on lifelong injections, expensive drugs, and cold-chain storage. And they leave patients stuck in maintenance, not recovery.
Hummsa Is Changing That.
We’re building a new kind of therapy. One that doesn’t just manage disease, but helps the body repair itself.
Our lead candidate, HB PKO02, an oral small molecule GLP-1 Receptor Agonist is designed to regenerate insulin-producing beta cells. By restoring lost function, it reduces or even eliminates the need for insulin. And because it targets damage early, it can be used to prevent, not just treat, disease.
Contact us
Phone
